Immunization for Streptococcus pneumoniae infections in high-risk children

Carrie L. Byington, Yvonne A. Maldonado, Elizabeth D. Barnett, Herbert Dele Davies, Kathryn M. Edwards, Mary Anne Jackson, Dennis L. Murray, Mobeen H. Rathore, Mark H. Sawyer, Gordon E. Schutze, Rodney E. Willoughby, Theoklis E. Zaoutis, Jennifer M. Frantz, Doug Campos-Outcalt, Marc A. Fischer, Bruce G. Gellin, Richard L. Gorman, Lucia H. Lee, R. Douglas Pratt, Joan L. RobinsonMarco Aurelio Palazzi Safadi, Jane F. Seward, Jeffrey R. Starke, Geoffrey R. Simon, Tina Q. Tan

Research output: Contribution to journalShort survey

9 Citations (Scopus)

Abstract

Routine use of the pneumococcal conjugate vaccines (PCV7 and PCV13), beginning in 2000, has resulted in a dramatic reduction in the incidence of invasive pneumococcal disease (IPD) attributable to serotypes of Streptococcus pneumoniae contained in the vaccines. The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention and the American Academy of Pediatrics recommend the expanded use of PCV13 in children 6 through 18 years of age with certain conditions that place them at elevated risk of IPD. This statement provides recommendations for the use of PCV13 in children 6 through 18 years. A single dose of PCV13 should be administered to certain children in this age group who are at elevated risk of IPD. Recommendations for the use of PCV13 in healthy children and for pneumococcal polysaccharide vaccine (PPSV23) remain unchanged.

Original languageEnglish (US)
Pages (from-to)1230-1233
Number of pages4
JournalPediatrics
Volume134
Issue number6
DOIs
StatePublished - Dec 1 2014

Fingerprint

Pneumococcal Infections
Immunization
Pneumococcal Vaccines
Conjugate Vaccines
Advisory Committees
Centers for Disease Control and Prevention (U.S.)
Streptococcus pneumoniae
Vaccines
Age Groups
Pediatrics
Pneumonia
Infection
Incidence
Vaccine

Keywords

  • Immunization
  • Invasive pneumococcal disease
  • PCV13
  • PPSV23
  • Pneumococcal vaccine

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Byington, C. L., Maldonado, Y. A., Barnett, E. D., Davies, H. D., Edwards, K. M., Jackson, M. A., ... Tan, T. Q. (2014). Immunization for Streptococcus pneumoniae infections in high-risk children. Pediatrics, 134(6), 1230-1233. https://doi.org/10.1542/peds.2014-2811

Immunization for Streptococcus pneumoniae infections in high-risk children. / Byington, Carrie L.; Maldonado, Yvonne A.; Barnett, Elizabeth D.; Davies, Herbert Dele; Edwards, Kathryn M.; Jackson, Mary Anne; Murray, Dennis L.; Rathore, Mobeen H.; Sawyer, Mark H.; Schutze, Gordon E.; Willoughby, Rodney E.; Zaoutis, Theoklis E.; Frantz, Jennifer M.; Campos-Outcalt, Doug; Fischer, Marc A.; Gellin, Bruce G.; Gorman, Richard L.; Lee, Lucia H.; Pratt, R. Douglas; Robinson, Joan L.; Safadi, Marco Aurelio Palazzi; Seward, Jane F.; Starke, Jeffrey R.; Simon, Geoffrey R.; Tan, Tina Q.

In: Pediatrics, Vol. 134, No. 6, 01.12.2014, p. 1230-1233.

Research output: Contribution to journalShort survey

Byington, CL, Maldonado, YA, Barnett, ED, Davies, HD, Edwards, KM, Jackson, MA, Murray, DL, Rathore, MH, Sawyer, MH, Schutze, GE, Willoughby, RE, Zaoutis, TE, Frantz, JM, Campos-Outcalt, D, Fischer, MA, Gellin, BG, Gorman, RL, Lee, LH, Pratt, RD, Robinson, JL, Safadi, MAP, Seward, JF, Starke, JR, Simon, GR & Tan, TQ 2014, 'Immunization for Streptococcus pneumoniae infections in high-risk children', Pediatrics, vol. 134, no. 6, pp. 1230-1233. https://doi.org/10.1542/peds.2014-2811
Byington CL, Maldonado YA, Barnett ED, Davies HD, Edwards KM, Jackson MA et al. Immunization for Streptococcus pneumoniae infections in high-risk children. Pediatrics. 2014 Dec 1;134(6):1230-1233. https://doi.org/10.1542/peds.2014-2811
Byington, Carrie L. ; Maldonado, Yvonne A. ; Barnett, Elizabeth D. ; Davies, Herbert Dele ; Edwards, Kathryn M. ; Jackson, Mary Anne ; Murray, Dennis L. ; Rathore, Mobeen H. ; Sawyer, Mark H. ; Schutze, Gordon E. ; Willoughby, Rodney E. ; Zaoutis, Theoklis E. ; Frantz, Jennifer M. ; Campos-Outcalt, Doug ; Fischer, Marc A. ; Gellin, Bruce G. ; Gorman, Richard L. ; Lee, Lucia H. ; Pratt, R. Douglas ; Robinson, Joan L. ; Safadi, Marco Aurelio Palazzi ; Seward, Jane F. ; Starke, Jeffrey R. ; Simon, Geoffrey R. ; Tan, Tina Q. / Immunization for Streptococcus pneumoniae infections in high-risk children. In: Pediatrics. 2014 ; Vol. 134, No. 6. pp. 1230-1233.
@article{728d01169fed46fbafe50c42e7593e22,
title = "Immunization for Streptococcus pneumoniae infections in high-risk children",
abstract = "Routine use of the pneumococcal conjugate vaccines (PCV7 and PCV13), beginning in 2000, has resulted in a dramatic reduction in the incidence of invasive pneumococcal disease (IPD) attributable to serotypes of Streptococcus pneumoniae contained in the vaccines. The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention and the American Academy of Pediatrics recommend the expanded use of PCV13 in children 6 through 18 years of age with certain conditions that place them at elevated risk of IPD. This statement provides recommendations for the use of PCV13 in children 6 through 18 years. A single dose of PCV13 should be administered to certain children in this age group who are at elevated risk of IPD. Recommendations for the use of PCV13 in healthy children and for pneumococcal polysaccharide vaccine (PPSV23) remain unchanged.",
keywords = "Immunization, Invasive pneumococcal disease, PCV13, PPSV23, Pneumococcal vaccine",
author = "Byington, {Carrie L.} and Maldonado, {Yvonne A.} and Barnett, {Elizabeth D.} and Davies, {Herbert Dele} and Edwards, {Kathryn M.} and Jackson, {Mary Anne} and Murray, {Dennis L.} and Rathore, {Mobeen H.} and Sawyer, {Mark H.} and Schutze, {Gordon E.} and Willoughby, {Rodney E.} and Zaoutis, {Theoklis E.} and Frantz, {Jennifer M.} and Doug Campos-Outcalt and Fischer, {Marc A.} and Gellin, {Bruce G.} and Gorman, {Richard L.} and Lee, {Lucia H.} and Pratt, {R. Douglas} and Robinson, {Joan L.} and Safadi, {Marco Aurelio Palazzi} and Seward, {Jane F.} and Starke, {Jeffrey R.} and Simon, {Geoffrey R.} and Tan, {Tina Q.}",
year = "2014",
month = "12",
day = "1",
doi = "10.1542/peds.2014-2811",
language = "English (US)",
volume = "134",
pages = "1230--1233",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "6",

}

TY - JOUR

T1 - Immunization for Streptococcus pneumoniae infections in high-risk children

AU - Byington, Carrie L.

AU - Maldonado, Yvonne A.

AU - Barnett, Elizabeth D.

AU - Davies, Herbert Dele

AU - Edwards, Kathryn M.

AU - Jackson, Mary Anne

AU - Murray, Dennis L.

AU - Rathore, Mobeen H.

AU - Sawyer, Mark H.

AU - Schutze, Gordon E.

AU - Willoughby, Rodney E.

AU - Zaoutis, Theoklis E.

AU - Frantz, Jennifer M.

AU - Campos-Outcalt, Doug

AU - Fischer, Marc A.

AU - Gellin, Bruce G.

AU - Gorman, Richard L.

AU - Lee, Lucia H.

AU - Pratt, R. Douglas

AU - Robinson, Joan L.

AU - Safadi, Marco Aurelio Palazzi

AU - Seward, Jane F.

AU - Starke, Jeffrey R.

AU - Simon, Geoffrey R.

AU - Tan, Tina Q.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Routine use of the pneumococcal conjugate vaccines (PCV7 and PCV13), beginning in 2000, has resulted in a dramatic reduction in the incidence of invasive pneumococcal disease (IPD) attributable to serotypes of Streptococcus pneumoniae contained in the vaccines. The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention and the American Academy of Pediatrics recommend the expanded use of PCV13 in children 6 through 18 years of age with certain conditions that place them at elevated risk of IPD. This statement provides recommendations for the use of PCV13 in children 6 through 18 years. A single dose of PCV13 should be administered to certain children in this age group who are at elevated risk of IPD. Recommendations for the use of PCV13 in healthy children and for pneumococcal polysaccharide vaccine (PPSV23) remain unchanged.

AB - Routine use of the pneumococcal conjugate vaccines (PCV7 and PCV13), beginning in 2000, has resulted in a dramatic reduction in the incidence of invasive pneumococcal disease (IPD) attributable to serotypes of Streptococcus pneumoniae contained in the vaccines. The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention and the American Academy of Pediatrics recommend the expanded use of PCV13 in children 6 through 18 years of age with certain conditions that place them at elevated risk of IPD. This statement provides recommendations for the use of PCV13 in children 6 through 18 years. A single dose of PCV13 should be administered to certain children in this age group who are at elevated risk of IPD. Recommendations for the use of PCV13 in healthy children and for pneumococcal polysaccharide vaccine (PPSV23) remain unchanged.

KW - Immunization

KW - Invasive pneumococcal disease

KW - PCV13

KW - PPSV23

KW - Pneumococcal vaccine

UR - http://www.scopus.com/inward/record.url?scp=84913537300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84913537300&partnerID=8YFLogxK

U2 - 10.1542/peds.2014-2811

DO - 10.1542/peds.2014-2811

M3 - Short survey

C2 - 25422018

AN - SCOPUS:84913537300

VL - 134

SP - 1230

EP - 1233

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 6

ER -